Study of new special immunosuppressive strategy for ABO incompatible transplantation

在日本，移植物的短缺鼓励我们进行跨越ABO血液屏障的活体肝移植（LDLT）。为了决定对ABO-I受体的治疗，抗A/B抗体（Ab）的量是非常重要的。目前，抗A/B Ab的数量以凝集滴度表示。本研究建立了一种检测抗A/B Ab的酶联免疫吸附试验（ELISA），并对其在临床应用中的价值进行了评价。抗A/B抗体效价中等。然而，在对每个接受者的评估中，O.D.抗A/B抗体效价为强或中等。结论：本研究建立的ELISA方法可用于检测抗A/B抗体的变化，并有可能应用于临床。

In Japan, the shortage of grafts has encouraged us to perform living donor liver transplantation (LDLT) across the ABO blood barrier. To decide the treatment for an ABO-I recipient, the amount of anti-A/B antibody (Ab) is very important. At present, the quantity of anti-A/B Ab is represented by the agglutination titer. We developed an enzyme linked immunosorbent assay (ELISA) to measure anti-A/B Ab, and assessed its usefulness in clinical practice in this study.In the assessment of all sera, the correlation between the O.D. and the titer of anti-A/B Ab were moderate. However, in the assessment of each recipient, the correlation between the O.D. and the titer of anti-A/B Ab was strong or moderate. Moreover, this investigation suggested that with our method it was possible to detect Ab-mediated rejection much earlier.In conclusion, our ELISA method is useful to detect changes in individually anti-A/B Ab and may have the possibility of using ELISA in clinical cases.